Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 78 (18), 1913-1924

Enzalutamide: A Review in Castration-Resistant Prostate Cancer

Affiliations
Review

Enzalutamide: A Review in Castration-Resistant Prostate Cancer

Lesley J Scott. Drugs.

Abstract

Oral enzalutamide (Xtandi®), a second generation androgen receptor inhibitor, is indicated for the treatment of castration-resistant prostate cancer (CRPC) in numerous countries worldwide, with specific indications in this patient population varying between individual countries. Based on extensive experience in the clinical trial and/or real-world settings, oral enzalutamide 160 mg once daily is an effective and generally well tolerated treatment in a broad spectrum of patients with CRPC, including in nonmetastatic and metastatic disease and in chemotherapy-naive and -experienced metastatic CRPC. Enzalutamide is an emerging option for the treatment of men with nonmetastatic CRPC who are at high-risk for developing metastatic disease, and remains an important first-line option in chemotherapy-naive or -experienced patients with metastatic CRPC.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Science. 2009 May 8;324(5928):787-90 - PubMed
    1. N Engl J Med. 2012 Sep 27;367(13):1187-97 - PubMed
    1. Drugs. 2013 Oct;73(15):1723-32 - PubMed
    1. Ann Oncol. 2014 Feb;25(2):429-34 - PubMed
    1. N Engl J Med. 2014 Jul 31;371(5):424-33 - PubMed

MeSH terms

LinkOut - more resources

Feedback